

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: DALE B. SCHENKApplication No./Patent No.: 10/816529; 6818218 Filed/Issue Date: March 31, 2004; November 16, 2004Titled: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASEJanssen Alzheimer Immunotherapy, a Corporation

(Name of Assignees)

(Type of Assignee: corporation, partnership, university, government agency, etc.)

states that they are:

1. ☒ the assignee of the entire right, title, and interest in;
2. ☐ an assignee of less than the entire right, title, and interest in
(The extent (by percentage) of its ownership interest is _____ %); or
3. ☐ Janssen Alzheimer Immunotherapy and Wyeth LLC are each an assignee of an undivided right, title, and interest in the patent application identified above. There are no other assignees.

the patent application/patent identified above, by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: DALE B. SCHENK To: ELAN PHARMACEUTICALS, INC.

The document was recorded in the United States Patent and Trademark Office at

Reel 022714, Frame 0495, or for which a copy thereof is attached.2. From: DALE B. SCHENK To: ATHENA NEUROSCIENCES, INC.

The document was recorded in the United States Patent and Trademark Office at

Reel 023304, Frame 0775, or for which a copy thereof is attached.3. From: ATHENA NEUROSCIENCES, INC. To: ELAN PHARMACEUTICALS, INC.

The document was recorded in the United States Patent and Trademark Office at

Reel 023304, Frame 0784, or for which a copy thereof is attached.

- ☒ Additional documents in the chain of title are listed on a supplemental sheet (s).

- ☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

Date

Rosemarie L. Celli Registration No. 42,397

Printed or Typed Name

7/30/2000

Title

Supplemental Sheet to Statement Under 3.73(b)
Attorney Docket No.: 057437-391527
Application No.: 10/816,529
Filing Date: March 31, 2004

Additional documents in the chain of title:

4. From: ELAN PHARMACEUTICALS, INC To: NEURALAB LIMITED
The document was recorded in the United States Patent and Trademark Office at Reel: 022714 Frame: 0821; or for which a copy thereof is attached.
5. From: NEURALAB LIMITED To: ELAN PHARMA INTERNATIONAL LIMITED
The document was recorded in the United States Patent and Trademark Office at Reel: 022714 Frame: 0948; or for which a copy thereof is attached.
6. From: ELAN PHARMA INTERNATIONAL LIMITED To: CRIMAGUA LIMITED
The document was recorded in the United States Patent and Trademark Office at Reel: 023337 Frame: 0495; or for which a copy thereof is attached.
7. From: CRIMAGUA LIMITED To: JANSSEN ALZHEIMER IMMUNOTHERAPY
The document was recorded in the United States Patent and Trademark Office at Reel: 023337 Frame: 0578; or for which a copy thereof is attached.